21+ · All compounds referenced are for laboratory research use only — read our disclaimer
PeptideCrib.
MetabolicWeight Loss

5-Amino-1MQ

5-Amino-1MQ is a small-molecule NNMT inhibitor researched for its effects on metabolism, fat tissue, and cellular energy pathways.

Updated July 26, 2026

21+ · Research use only: all compounds referenced on this site are intended strictly for laboratory research and are not for human consumption. Nothing here is medical advice.

What is 5-Amino-1MQ?

5-Amino-1MQ is a small molecule that has been investigated for potential roles in metabolism regulation and fat loss. It is technically not a peptide but is often categorized with various peptide research compounds. 5-Amino-1MQ functions by selectively inhibiting the NNMT (nicotinamide N-methyltransferase) enzyme. This enzyme is associated with increased fat accumulation and metabolic disruptions. Inhibiting it may also enhance intracellular levels of the NAD+. The compound is commonly supplied in oral capsule form, though research can be found utilizing other administration methods as well. It may be sold in a vial format for administration.RESEARCHUSE ONLY 5-Amino-1MQ is intended for use by qualified researchers only.

Researched effects

Summaries of effects discussed in the research literature for 5-Amino-1MQ. Laboratory research context only — not outcomes promised for people.

NNMT InhibitionResearch shows 5-Amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT), an enzyme related to fat accumulation.
NAD+ Level SupportReports suggest it increases cellular NAD+ by interfering with methyl group depletion.
Metabolic HealthPreclinical studies indicate potential improvements in metabolic markers and fat tissue function.
Fat Loss MechanismExperimental results demonstrate reduction of white adipose tissue in animal research.
Insulin SensitivityResearch suggests possible improvements in insulin sensitivity linked to metabolic effects.
Cellular EnergyEnhanced mitochondrial energy production is under investigation via raised NAD+ pools.

Research observation timeline

A neutral map of what studies report over time. Illustrative of the literature, not a schedule or a promise of results.

  1. 1
    Early in-vitro studies

    Inhibition of NNMT enzyme activity observed in cell assays.

    Studies focus on enzymatic pathways and NAD+ conservation mechanisms.

  2. 2
    Animal models

    Reductions in fat mass and improvements in insulin sensitivity recorded in rodents.

    Reports highlight metabolic and energetic improvements; effects extrapolated from animal physiology.

  3. 3
    Research-community reports

    Anecdotal findings describe fat loss and higher energy.

    Research-context use is discussed but lacks controlled human trial confirmation.

  4. 4
    Regulatory status review (2026)

    Not FDA-approved and lacks human clinical trial data.

    Continued interest in applications for obesity, metabolic syndrome, and insulin resistance.

Timelines vary across studies and models. Nothing here describes human dosing or use.

Top 5-Amino-1MQ vendors

Vendors from our reviewed inventory tagged as carrying 5-Amino-1MQ, newest first. Affiliate links may earn us a commission; listing order is by recency, not payment.

Handling & storage reference

Storage form, reconstitution, and stability at a glance. Educational reference for lab handling — never a human dosing instruction.

Physical formSupplied as either oral capsules or lyophilized powder in vials.
ReconstitutionLyophilized powder may require laboratory reconstitution with appropriate solvent for in vitro or animal studies.
Powder storageStore lyophilized powder at -20°C, protected from light and moisture.
Reconstituted storageAfter reconstitution, store at 2-8°C for short-term lab use.
Shelf lifeLyophilized form may be stable for up to 24 months under proper laboratory storage.
Evidence levelPreclinical (animal / in-vitro only)
Compound class
Small-molecule NNMT inhibitor
Molecular family
Quinolinium derivatives
Research application
Metabolic and obesity studies
Regulatory status
Not FDA-approved; research-use only

Handling notesNo human phase studies published as of June 2026; use remains experimental for all lab research.

Reconstituted Vial Expiry & Storage

General handling guidance for research materials — not medical advice.

Lyophilised powderFridge 2–8°C (weeks–months) · freezer −20°C (long-term). Keep dark and dry.
Reconstituted (BAC water)Refrigerate 2–8°C. Commonly treated as a ~28-day window. Do not freeze.
Reconstituted (sterile water)No preservative — single-session use; do not store for multiple draws.

Reconstitution & dilution math

5-Amino-1MQ is generally sold in vacuum sealed vials, Iyophilized powder, and sometimes as a ready oral solution. It is is supplied to the laboratory in a lyopholized (dehydrated) form, which must typically be dissolved in sterile solvent or buffer before use in assays. Confirm all aspects of solubility and suitability for use with your experimental plan.

Open the Reconstitution Calculator →

Educational aid for handling research materials — not medical advice or a dosing recommendation.

Safety notes (research settings)

Proper laboratory procedures should be followed during handling. Wear gloves and eye protection. Containment should be used appropriately. The substance is not intended for internal use (ingestion, inhalation, or injection) except in appropriate research protocols, and not for human or veterinary treatment. Consult your institution guidelines on storage, disposal of chemicals and Safety procedures.

Legal status

5-Amino-1MQ is not FDA approved as medicine as of June 2026 and is generally sold labeled “for research use only” by most suppliers. There have been no human published clinical trials registered for this compound. Be advised, you will need to consult with local, institutional and national governments before ordering or working with 5-Amino-1MQ in any research protocol. It should not be used as part of diagnosis or treatment.

Frequently asked questions

What does 5-Amino-1MQ target in research?

5-Amino-1MQ is studied for its ability to block the NNMT enzyme, which impacts fat metabolism and cellular NAD+ levels.

Is 5-Amino-1MQ a peptide?

No, it is a small molecule, not a peptide. However, they often list it alongside peptides for research use.

What is the route of administration in research?

They commonly supply 5-Amino-1MQ as an oral capsule. Some research sources also carry it in lyophilized vial form for subcutaneous use.

Is 5-Amino-1MQ legal for research?

As of June 2026, 5-Amino-1MQ is legal when used for preclinical laboratory research. It is not FDA-approved for medical or therapeutic use.

Where can I find human trial data for 5-Amino-1MQ?

No published human clinical trials are available for 5-Amino-1MQ as of June 2026. Current information comes from animal studies and in vitro research.

Sources & research

Every source below was opened and checked by an editor before it was listed. Tags show what kind of evidence each one is — most research-peptide literature is preclinical, and we label it that way.

  1. Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice — Biochemical Pharmacology, 2018 Animal study
  2. Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction — PubMed (peer-reviewed), 2024
  3. Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity — Nature, 2014 Animal study
  4. Sampson CM, Dimet AL, Neelakantan H, et al. Combined nicotinamide N-methyltransferase inhibition and lean-diet substitution reduces body weight and liver fat in obese mice — Scientific Reports, 2021 Animal study
  5. Pissios P. Nicotinamide N-Methyltransferase: More Than a Vitamin B3 Clearance Enzyme — Trends in Endocrinology and Metabolism, 2017 Review / meta-analysis
  6. National Center for Biotechnology Information. PubChem Compound Summary for 5-Amino-1-methylquinolinium (5-Amino-1MQ) — PubChem, 2026 Reference database
  7. U.S. Food and Drug Administration. Drugs@FDA: search confirms no approved 5-Amino-1MQ product as of June 2026 — FDA.gov, 2026 Regulatory / official
  8. ClinicalTrials.gov. Search results for 5-Amino-1MQ and NNMT inhibitor (no active human trials registered as of June 2026) — ClinicalTrials.gov, 2026 Regulatory / official

Links open on the publisher or database site. Citations describe laboratory research; none of them establishes a human use for this compound.

Affiliate disclosure: we may earn a commission when you buy through links on this page, at no extra cost to you. Commissions never influence our ratings — see how we verify.